| Literature DB >> 24714086 |
Sonja M Kessler1, Yvette Simon2, Katja Gemperlein3, Kathrin Gianmoena4, Cristina Cadenas5, Vincent Zimmer6, Juliane Pokorny7, Ahmad Barghash8, Volkhard Helms9, Nico van Rooijen10, Rainer M Bohle11, Frank Lammert12, Jan G Hengstler13, Rolf Mueller14, Johannes Haybaeck15, Alexandra K Kiemer16.
Abstract
Non-alcoholic steatohepatitis (NASH) represents a risk factor for the development of hepatocellular carcinoma (HCC) and is characterized by quantitative and qualitative changes in hepatic lipids. Since elongation of fatty acids from C16 to C18 has recently been reported to promote both hepatic lipid accumulation and inflammation we aimed to investigate whether a frequently used mouse NASH model reflects this clinically relevant feature and whether C16 to C18 elongation can be observed in HCC development. Feeding mice a methionine and choline deficient diet to model NASH not only increased total hepatic fatty acids and cholesterol, but also distinctly elevated the C18/C16 ratio, which was not changed in a model of simple steatosis (ob/ob mice). Depletion of Kupffer cells abrogated both quantitative and qualitative methionine-and-choline deficient (MCD)-induced alterations in hepatic lipids. Interestingly, mimicking inflammatory events in early hepatocarcinogenesis by diethylnitrosamine-induced carcinogenesis (48 h) increased hepatic lipids and the C18/C16 ratio. Analyses of human liver samples from patients with NASH or NASH-related HCC showed an elevated expression of the elongase ELOVL6, which is responsible for the elongation of C16 fatty acids. Taken together, our findings suggest a detrimental role of an altered fatty acid pattern in the progression of NASH-related liver disease.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24714086 PMCID: PMC4013594 DOI: 10.3390/ijms15045762
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1.Non-alcoholic steatohepatitis (NASH), but not non-alcoholic fatty liver disease (NAFLD), is accompanied by elevation of C18 over C16. (A) Representative liver sections stained with hematoxylin-eosin (HE) from animals fed with either a methionine-choline deficient (MCD) or a control (crtl) diet for 3 weeks (original magnification 200×). Arrows denote inflammatory foci; (B) Sum of all hepatic fatty acids, hepatic cholesterol, and ratio of hepatic C18/C16 fatty acids of MCD fed animals compared to ctrl were analyzed by GC-MS (gas chromatography-mass spectrometry) (n = 9–10); and (C,D) Representative HE-stained liver sections (C), hepatic fatty acids as well as hepatic cholesterol, and ratio of hepatic C18/C16 fatty acids (D) of ob/+ and ob/ob mice (n = 8).
Figure 2.Kupffer cell depletion abrogated elevation of C18 over C16. (A) Representative liver sections immunohistologically stained against F4/80 as Kupffer cell marker from animals fed with the respective diet for 3 weeks with simultaneous administration of clodronate (clo) or empty (sham) liposomes (original magnification 200×); and (B,C) Increase of the sum of all hepatic fatty acids, hepatic cholesterol (B), and ratio of hepatic C18/C16 fatty acids (C) of MCD fed animals treated with clodronate (clo) or empty (sham) liposomes compared to ctrl analyzed by GC-MS (n = 9–10).
Figure 3.(A) Representative liver sections stained with HE from animals treated with DEN (DEN) compared to untreated control (crtl) (original magnification 200×). Arrows denote inflammatory foci; (B) Sum of all fatty acids, hepatic cholesterol, and ratio of C18/C16 fatty acids of DEN treated animals compared to untreated control (ctrl) are displayed (n = 6–15); (C,D) Expression of ELOVL6 in human NASH (n = 18) compared to steatosis (n = 14) (GSE48452) (n.s. = not statistically significant) (C) as well as healthy control samples (n = 8 for NASH; n = 7 for control; GSE37031) (D); and (E) ELOVL6 mRNA expression in human NASH-related HCC samples (NASH-HCC) (n = 6) compared to HCC with mixed etiology (mixed HCC) (n = 26) [40]. Expression of tumor tissues was normalized to matched normal liver tissue (matched control).